Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients

Strategy on the Increment of H. Pylori Eradication Rate and Investigating the Gastric Pathology and Antimicrobial Resistance in Diabetic Patients

The study aims to evaluate H. pylori eradication rate in diabetic patients by using novel 10-day levofloxacin-based concomitant therapy compared with conventional 10-day sequential therapy.

Inclusion Criteria:

• Diabetic patients with Helicobacter pylori infection

Exclusion Criteria:

• Pregnancy or physically poor performance status
• Patients with contraindication for upper endoscopy
• Severe coagulopathy for endoscopic biopsy
• Chronic kidney disease (eGFR < 50) or end stage renal disease
• Known allergy to interventional drugs
• Previous eradication failure